If you are wondering whether Guardant Health's recent run justifies the current share price, this article will walk through ...

Guardant co-CEO Helmy Eltoukhy says the shift to personalized treatment and earlier diagnosis is here at the WIRED Health ...

The medical services stock holds a Relative Strength Rating of 97 out of a best-possible 99. Meanwhile, its all-around ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS study supporting the use of Guardant Reveal to ...

Guardant Health's Shield blood test for colorectal cancer screening is now covered by TRICARE, providing active duty service ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for ...

Fintel reports that on January 5, 2026, Evercore ISI Group downgraded their outlook for Guardant Health (NasdaqGS:GH) from ...

New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity Reveal is ...

Guardant Health scientists have created the first blood-based test to screen for colorectal cancer that Medicare could cover. Guardant Health scientists have created the first blood-based test to ...

I was a little late to the party in buying Guardant Health (GH 0.75%). After watching the stock soar during the latter part of 2018 and the first half of 2019, I finally jumped in to scoop up shares ...